Status report
Get it in writing
The official USPTO status record for REIMBURSEMENT ACCESS FOUNDATION & ADJUDICATION, serial 87758608, as a dated PDF. One price, one document, delivered in about a minute.
INSTANT DELIVERY
Trademark Status Report
$7.99
The USPTO's own status record for this mark, on one dated page.
- Current status with a plain-English verdict
- Owner, classes, filing basis, and every key date
- The mark as it appears on the federal record
- Every prosecution event, filing to today
- Source-cited with the exact retrieval date
Built from the USPTO's TSDR record. Assignment chain of title and TTAB proceeding files sit in separate USPTO systems and are not included.
Preview
◆ TRADEMARKCHECKER.AITRADEMARK STATUS REPORT
REIMBURSEMENT ACCESS FOUNDATION & ADJUDICATIONSerial 87758608 · Principal Register
Dead · Refused
Owner: Bristol-Myers Squibb Company
Class 009 - Electrical & Scientific Apparatus
Class 042 - Scientific & Technology Services
Filed Jan 17, 2018
The record shows that the mark REIMBURSEMENT ACCESS FOUNDATION & ADJUDICATION was filed by Bristol‑Myers Squibb Company on Jan 17 2018, but it was abandoned on Nov 17 2018 after the applicant failed to respond to an Office action, so the application is dead and never entered the register. The goods and services listed are analytical software that uses an electronic record infrastructure—including a patient’s medical information and treatment history—to determine value‑based drug prices agreed between payers and pharmaceutical companies (Class 009), and a business method that uses the same electronic record infrastructure for that pricing purpose (Class 042). A similar name used in connection with software or pricing services for health‑care data would raise the closest record‑based concern, while uses in unrelated fields would be farther from the scope shown. The prosecution history contains only the non‑final action and the abandonment notices; no oppositions, cancellations or court actions appear, so the supplied history shows no enforcement activity. I'd treat this as a meaningful concern if you plan to brand a health‑data pricing platform with a comparable name.
Full event history, owner details, and verdict inside.
The way I'd use it, honestly, is as the thing you attach when a bank, a marketplace, or a co-founder asks "are we clear on the name". It answers in one page.